New compounds to treat liver damage from viral hepatitis
Non-immunosuppressive Sanglifehrin Analogs as Therapeutic Agents for Viral Hepatitis-induced Liver Damage Development
This study is looking at new medicines that might help protect your liver from damage caused by Hepatitis B and C, and it’s for people who are dealing with these viruses and their related liver cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Scripps Research Institute, the NIH-funded |
| Lab location | 1 site (La Jolla, United States) |
| Project ID | NIH-10817157 on NIH RePORTER |
What this research studies
This research focuses on developing a new class of compounds called sanglifehrin derivatives (SfDer) that have the potential to prevent liver damage caused by viral hepatitis, specifically targeting Hepatitis B and C. The approach involves testing these compounds for their ability to inhibit the replication of the viruses and their associated liver cancer, hepatocellular carcinoma (HCC). By exploring novel drug combinations, the research aims to address the significant public health issue of HCC recurrence and treatment failure in patients with viral hepatitis. Patients may be involved in trials to assess the effectiveness and safety of these new therapeutic agents.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with chronic Hepatitis B or C who are at risk of developing hepatocellular carcinoma.
Not a fit: Patients who do not have viral hepatitis or those with advanced liver disease not related to viral infections may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients suffering from liver damage due to viral hepatitis, potentially reducing the risk of liver cancer.
How similar studies have performed: Other research has shown promise in developing novel therapeutic agents for viral hepatitis and associated liver conditions, indicating a potential for success with this approach.
Where this research is happening
La Jolla, United States
- Scripps Research Institute, the — La Jolla, United States (Active)
Researchers
- Principal investigator: Gallay, Philippe Andre — Scripps Research Institute, the
- Study coordinator: Gallay, Philippe Andre
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.